ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Saturday, July 19, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Coronavirus

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization

The FINANCIAL by The FINANCIAL
March 12, 2021
in Coronavirus
Reading Time: 4 mins read
8
A A
0
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Share on FacebookShare on Twitter

The FINANCIAL — Data have demonstrated vaccine protects against COVID-19 related hospitalization and death in broad geographic regions, including those with variants of significant concern. Available on not-for-profit basis for emergency pandemic use. Compatible with standard vaccine storage, distribution channels, enabling delivery to remote areas

Johnson & Johnson announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.

According to Johnson & Johnson, data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants given the placebo. The onset of protection was observed from day 14 and was maintained 28 days post-vaccination.

The data also demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death across countries with different variants, beginning 28 days after vaccination.1 Variants observed in an ongoing analysis in the ENSEMBLE study included the B.1.351 variant which was identified in 95 percent of the COVID-19 cases in South Africa.

“From the beginning of the pandemic, we have worked to develop and deliver a vaccine that could protect the health of people everywhere, and today’s milestone represents significant progress toward ensuring global access to our single-shot vaccine,” said Alex Gorsky, Chairman and Chief Executive Officer at Johnson & Johnson. “We are moving forward with urgency and purpose to meet our commitments to the global community as we do all we can to help end the pandemic.”

The EUL procedure streamlines the process by which new or unlicensed products can be assessed for use during public health emergencies by governments and United Nations procurement agencies. The EUL process expedites access to such products in many countries around the world and is also a prerequisite to supply vaccines to the new COVAX Facility, a global mechanism for pooled procurement and distribution of COVID-19 vaccines in 190 participating countries, including 92 lower-income countries Johnson & Johnson notes.

“The WHO listing of our single-shot COVID-19 vaccine advances our pledge to help stem this pandemic and our unwavering commitment to equitable access,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “Achieving this important prerequisite for distributing our vaccine through the COVAX Facility which is co-led by Gavi is a major step forward in making our vaccine accessible for all.”

In December 2020, Johnson & Johnson entered into an agreement in principle with Gavi, the Vaccine Alliance (Gavi) in support of the COVAX Facility. Johnson & Johnson and Gavi expect to enter into an Advance Purchase Agreement (APA) that would provide up to 500 million doses of the Company’s vaccine to COVAX through 2022.

“A single-shot COVID-19 vaccine that can be distributed and stored using established supply chains has the potential to be very meaningful in the face of this global pandemic,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development at Johnson & Johnson. “In addition, the clinical data shared with WHO that informed the Emergency Use Listing demonstrated protection against disease across countries with multiple variants.”

Commitment to Equitable Access
Equitable access is at the center of Johnson & Johnson’s COVID-19 response. The Johnson & Johnson single-shot vaccine candidate and its compatibility with standard vaccine distribution channels align with WHO’s recommendations for medical interventions in a pandemic setting, which emphasize ease of distribution, administration, and compliance.

The Company is committed to ensuring global access to the Johnson & Johnson single-shot COVID-19 vaccine candidate on a not-for-profit basis for emergency pandemic use. In September 2020, Johnson & Johnson joined other life sciences companies and the Bill & Melinda Gates Foundation in signing an unprecedented communiqué which outlined a steadfast commitment to facilitating equitable access to the innovations being developed to fight the pandemic, Johnson & Johnson notes.

Regulatory Filings
Johnson & Johnson received Emergency Use Authorization (EUA) in the United States on February 274 following a unanimous vote by the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee on February 26, 2021.5 The Company’s single-shot COVID-19 vaccine was also granted Interim Order authorization in Canada on March 5, 20216 and Conditional Marketing Authorization (CMA) in the European Union on March 11, 2021.7

Manufacturing and Supply Chain Information
The Johnson & Johnson COVID-19 single-shot vaccine is compatible with standard vaccine storage and distribution channels enabling delivery to remote areas.4 The vaccine is estimated to remain stable for two years at -25 to -15°C, and a maximum of three months of which can be at routine refrigeration at temperatures of 2°-8°C.4,8 This enables the vaccine to be shipped using the same cold chain technologies used to transport other medicines and vaccines in routine use.4,9

Johnson & Johnson’s COVID-19 Vaccine
The Johnson & Johnson COVID-19 vaccine uses the AdVac® vaccine platform, a proprietary technology that was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine regimen and construct its investigational Zika, RSV, and HIV vaccines.6

Phase 3 ENSEMBLE Study Design
The Phase 3 ENSEMBLE study is a randomized, double-blind, placebo-controlled clinical trial in individuals 18 years of age and older.10 The study was designed to evaluate the safety and efficacy of the Company’s vaccine candidate in protecting against both moderate and severe COVID-19 disease, with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints.11 The study enrolled a total of 43,783 participants.

The trial, conducted in eight countries across three continents,10 includes a diverse and broad population of which 34 percent of participants were over age 60.1 Forty-one percent of participants in the study had comorbidities associated with an increased risk for progression to severe COVID-19.1

RelatedPosts

Ann Arbor restaurants’ operator agrees to pay $197K in back wages, damages to 20 workers denied overtime during pandemic

Boston Public Health Commission Urges Residents To Get Updated COVID-19 Vaccine

After Four Years, 59% in U.S. Say COVID-19 Pandemic Is Over

Older US Adults Should Get Another COVID Shot, Say Health Officials

The FINANCIAL — Data have demonstrated vaccine protects against COVID-19 related hospitalization and death in broad geographic regions, including those with variants of significant concern. Available on not-for-profit basis for emergency pandemic use. Compatible with standard vaccine storage, distribution channels, enabling delivery to remote areas

Johnson & Johnson announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.

According to Johnson & Johnson, data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants given the placebo. The onset of protection was observed from day 14 and was maintained 28 days post-vaccination.

The data also demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death across countries with different variants, beginning 28 days after vaccination.1 Variants observed in an ongoing analysis in the ENSEMBLE study included the B.1.351 variant which was identified in 95 percent of the COVID-19 cases in South Africa.

“From the beginning of the pandemic, we have worked to develop and deliver a vaccine that could protect the health of people everywhere, and today’s milestone represents significant progress toward ensuring global access to our single-shot vaccine,” said Alex Gorsky, Chairman and Chief Executive Officer at Johnson & Johnson. “We are moving forward with urgency and purpose to meet our commitments to the global community as we do all we can to help end the pandemic.”

The EUL procedure streamlines the process by which new or unlicensed products can be assessed for use during public health emergencies by governments and United Nations procurement agencies. The EUL process expedites access to such products in many countries around the world and is also a prerequisite to supply vaccines to the new COVAX Facility, a global mechanism for pooled procurement and distribution of COVID-19 vaccines in 190 participating countries, including 92 lower-income countries Johnson & Johnson notes.

“The WHO listing of our single-shot COVID-19 vaccine advances our pledge to help stem this pandemic and our unwavering commitment to equitable access,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “Achieving this important prerequisite for distributing our vaccine through the COVAX Facility which is co-led by Gavi is a major step forward in making our vaccine accessible for all.”

In December 2020, Johnson & Johnson entered into an agreement in principle with Gavi, the Vaccine Alliance (Gavi) in support of the COVAX Facility. Johnson & Johnson and Gavi expect to enter into an Advance Purchase Agreement (APA) that would provide up to 500 million doses of the Company’s vaccine to COVAX through 2022.

“A single-shot COVID-19 vaccine that can be distributed and stored using established supply chains has the potential to be very meaningful in the face of this global pandemic,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development at Johnson & Johnson. “In addition, the clinical data shared with WHO that informed the Emergency Use Listing demonstrated protection against disease across countries with multiple variants.”

Commitment to Equitable Access
Equitable access is at the center of Johnson & Johnson’s COVID-19 response. The Johnson & Johnson single-shot vaccine candidate and its compatibility with standard vaccine distribution channels align with WHO’s recommendations for medical interventions in a pandemic setting, which emphasize ease of distribution, administration, and compliance.

The Company is committed to ensuring global access to the Johnson & Johnson single-shot COVID-19 vaccine candidate on a not-for-profit basis for emergency pandemic use. In September 2020, Johnson & Johnson joined other life sciences companies and the Bill & Melinda Gates Foundation in signing an unprecedented communiqué which outlined a steadfast commitment to facilitating equitable access to the innovations being developed to fight the pandemic, Johnson & Johnson notes.

Regulatory Filings
Johnson & Johnson received Emergency Use Authorization (EUA) in the United States on February 274 following a unanimous vote by the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee on February 26, 2021.5 The Company’s single-shot COVID-19 vaccine was also granted Interim Order authorization in Canada on March 5, 20216 and Conditional Marketing Authorization (CMA) in the European Union on March 11, 2021.7

Manufacturing and Supply Chain Information
The Johnson & Johnson COVID-19 single-shot vaccine is compatible with standard vaccine storage and distribution channels enabling delivery to remote areas.4 The vaccine is estimated to remain stable for two years at -25 to -15°C, and a maximum of three months of which can be at routine refrigeration at temperatures of 2°-8°C.4,8 This enables the vaccine to be shipped using the same cold chain technologies used to transport other medicines and vaccines in routine use.4,9

Johnson & Johnson’s COVID-19 Vaccine
The Johnson & Johnson COVID-19 vaccine uses the AdVac® vaccine platform, a proprietary technology that was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine regimen and construct its investigational Zika, RSV, and HIV vaccines.6

Phase 3 ENSEMBLE Study Design
The Phase 3 ENSEMBLE study is a randomized, double-blind, placebo-controlled clinical trial in individuals 18 years of age and older.10 The study was designed to evaluate the safety and efficacy of the Company’s vaccine candidate in protecting against both moderate and severe COVID-19 disease, with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints.11 The study enrolled a total of 43,783 participants.

The trial, conducted in eight countries across three continents,10 includes a diverse and broad population of which 34 percent of participants were over age 60.1 Forty-one percent of participants in the study had comorbidities associated with an increased risk for progression to severe COVID-19.1

Tags: Data have demonstrated vaccine protects against COVID-19 related hospitalization and death in broad geographic regionsdistribution channelsenabling delivery to remote areasincluding those with variants of significant concern. Available on not-for-profit basis for emergency pandemic use. Compatible with standard vaccine storagePharmaceutical Companies of Johnson & Johnson (Janssen)Single-Shot COVID-19 VaccineWorld Health Organization (WHO)

Related Posts

Ann Arbor restaurants’ operator agrees to pay $197K in back wages, damages to 20 workers denied overtime during pandemic
Americas

Ann Arbor restaurants’ operator agrees to pay $197K in back wages, damages to 20 workers denied overtime during pandemic

by The FINANCIAL
June 19, 2024
0

ANN ARBOR, MI – An Ann Arbor restaurant operator who sought and received nearly $950,000 in federal assistance to help...

Read more
Boston Public Health Commission Urges Residents To Get Updated COVID-19 Vaccine

Boston Public Health Commission Urges Residents To Get Updated COVID-19 Vaccine

March 16, 2024
After Four Years, 59% in U.S. Say COVID-19 Pandemic Is Over

After Four Years, 59% in U.S. Say COVID-19 Pandemic Is Over

March 16, 2024

Older US Adults Should Get Another COVID Shot, Say Health Officials

February 29, 2024

Discussion about this post

  • Trending
  • Comments
  • Latest
Teaching porn literacy

A sizable percentage of internet porn users, roughly 40% are women

January 17, 2024
Ampersand wins £22m five-year contract at London Zoo

Ampersand wins £22m five-year contract at London Zoo

June 25, 2012
EasyJet to fly to London from Stockholm Arlanda

The London Diplomatic List, Addresses, Contacts & Working Hours

January 23, 2023
Teaching porn literacy

Teaching porn literacy

January 17, 2024
OCCRP investigation: Danish Company Affiliate Helping Russians Export Grain From Occupied Ukraine

OCCRP investigation: Danish Company Affiliate Helping Russians Export Grain From Occupied Ukraine

July 16, 2025
OCCRP investigation: Danish Company Affiliate Helping Russians Export Grain From Occupied Ukraine

OCCRP investigation: Danish Company Affiliate Helping Russians Export Grain From Occupied Ukraine

July 16, 2025
How Mark Lamberti Challenged Retail Convention in the Last Days of Apartheid

How Mark Lamberti Challenged Retail Convention in the Last Days of Apartheid

July 16, 2025
Existing-Home Sales Spring Ahead in March

Should You Fix Up Your House or Sell It As-Is?

July 15, 2025
Richard Branson: What’s one daily habit that has shaped you as a person?

Richard Branson: What’s one daily habit that has shaped you as a person?

July 11, 2025
Most Americans continue to say media scrutiny keeps politicians from doing things they shouldn’t

Dramatic rise in the number of journalists killed in six months



July 11, 2025
ADVERTISEMENT

Popular Last 24h

  • Slightly over 26 000 victims of road accidents in the EU in 2015

    Slightly over 26 000 victims of road accidents in the EU in 2015

    27 shares
    Share 11 Tweet 7
  • Ampersand wins £22m five-year contract at London Zoo

    4164 shares
    Share 1666 Tweet 1041
  • The London Diplomatic List, Addresses, Contacts & Working Hours

    3404 shares
    Share 1362 Tweet 851
  • A sizable percentage of internet porn users, roughly 40% are women

    930 shares
    Share 372 Tweet 233
  • Teaching porn literacy

    371 shares
    Share 148 Tweet 93
  • A Landmark Rolls-Ryce Debut in Georgia

    160 shares
    Share 64 Tweet 40

LATEST POSTS

OCCRP investigation: Danish Company Affiliate Helping Russians Export Grain From Occupied Ukraine

OCCRP investigation: Danish Company Affiliate Helping Russians Export Grain From Occupied Ukraine

July 16, 2025
How Mark Lamberti Challenged Retail Convention in the Last Days of Apartheid

How Mark Lamberti Challenged Retail Convention in the Last Days of Apartheid

July 16, 2025
Existing-Home Sales Spring Ahead in March

Should You Fix Up Your House or Sell It As-Is?

July 15, 2025
Richard Branson: What’s one daily habit that has shaped you as a person?

Richard Branson: What’s one daily habit that has shaped you as a person?

July 11, 2025
Most Americans continue to say media scrutiny keeps politicians from doing things they shouldn’t

Dramatic rise in the number of journalists killed in six months



July 11, 2025
Euro area international trade in goods surplus €7.3 bn

Trade talks EU–US: Trade in services should be taken into account

July 11, 2025
Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

July 11, 2025
Update by The Florida Department of Transportation: Key Improvements

Update by The Florida Department of Transportation: Key Improvements

July 11, 2025
Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

July 11, 2025
Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

July 9, 2025

LATESTBUSINESS

Existing-Home Sales Spring Ahead in March

Should You Fix Up Your House or Sell It As-Is?

by The FINANCIAL
July 15, 2025
0

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

by The FINANCIAL
July 11, 2025
0

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

by The FINANCIAL
July 11, 2025
0

Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

by The FINANCIAL
July 9, 2025
0

wall_street_sign.jpg

Wall Street Giants Now Worth $59.7 Trillion, More Than the GDP of the U.S., China, and Germany Combined

by The FINANCIAL
July 9, 2025
0

Are You Really Targeting the Right Customer

Are You Really Targeting the Right Customer

by The FINANCIAL
July 8, 2025
0

Prominent Georgian Businessman Behind Euronews and National Geographic Arrested in Tbilisi

Prominent Georgian Businessman Behind Euronews and National Geographic Arrested in Tbilisi

by The FINANCIAL
July 7, 2025
0

Etisalat and Ericsson trial Massive MIMO technology in the UAE

Global study shows 96% plan to increase yield focus in anticipation of market correction

by The FINANCIAL
July 7, 2025
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+995 558) 03 03 03 Email: marketing (at) finchannel.com

Whatsup: (+995 599) 96 52 52

Georgia:

(+995 599) 96 52 52 Email: editor (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.